Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Bone Neoplasms
  • Cisplatin
  • Lung Neoplasms
  • Osteosarcoma

abstract

  • ILC is well tolerated in heavily treated osteosarcoma patients and did not appear to have the typical toxicities associated with intravenous cisplatin. Three of eight patients with less bulky disease had sustained benefit. Further study of ILC is warranted.

publication date

  • April 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/pbc.24438

PubMed ID

  • 23255417

Additional Document Info

start page

  • 580

end page

  • 6

volume

  • 60

number

  • 4